The global structural heart devices market has entered a period of strong and sustained expansion. Valued at USD 14.93 billion in 2023, the market grew to USD 16.31 billion in 2024 and is projected to reach USD 25.69 billion by 2029, reflecting a robust CAGR of 9.5%. This growth underscores a major transformation in cardiovascular care, driven by innovation in minimally invasive technologies, an aging global population, improved diagnostic accuracy, and expanding access to advanced cardiac procedures.
Key Market Drivers: What Is Fueling the Rapid Growth of Structural Heart Devices?
The rise of structural heart diseases worldwide—including aortic stenosis, mitral regurgitation, tricuspid valve disease, and congenital heart defects—is one of the most powerful forces shaping this market. As life expectancy increases, the prevalence of degenerative valvular conditions continues to climb, particularly in developed economies where the aging population forms a large patient pool.
1. Growing Burden of Valvular & Congenital Diseases
Globally, valvular heart diseases are rising sharply due to age-related degeneration, calcification, lifestyle factors, and increased early detection. This significantly expands the addressable market for both replacement and repair devices.
2. Shift Toward Minimally Invasive Structural Heart Interventions
Technologies such as Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Repair/Replacement (TMVR) have revolutionized treatment pathways. Key benefits include:
- Reduced hospital stays
- Lower complication rates
- Faster recovery
- Suitability for high-risk and inoperable patients
- Improved long-term outcomes
These advantages have accelerated physician and patient adoption globally.
3. Favorable Reimbursement Policies
Countries such as the U.S., Germany, France, Japan, and Canada have expanded reimbursement coverage for transcatheter procedures. This has dramatically improved patient accessibility and encouraged hospitals to upgrade structural heart programs.
4. Expanding Interventional Cardiology Infrastructure
Emerging economies—including India, China, Brazil, and Southeast Asian nations—are rapidly investing in cardiac cath labs, hybrid ORs, and physician training programs. This is boosting procedural volumes and enabling broader adoption of advanced structural heart solutions.
5. Innovation in Next-Generation Devices
Manufacturers continue to launch devices offering:
- Improved durability and biocompatibility
- Low-profile delivery systems
- Enhanced sealing and repositionability
- Better imaging integration
- Reduced risk of paravalvular leak
These advancements support wider use across diverse patient anatomies and clinical indications.
Together, these drivers create a powerful global momentum for the structural heart devices market—one of the most innovation-driven spaces in cardiovascular care.
Product Insights: Heart Valve Devices Hold the Largest Market Share in 2023
Among all product categories, heart valve devices—especially transcatheter heart valves—dominate the market in 2023.
Why Heart Valve Devices Lead the Market
The strong growth of the heart valve segment is directly tied to the success of TAVR and TMVR, which have shifted the treatment paradigm for aortic and mitral valve diseases. These devices are preferred due to:
- Their minimally invasive nature
- Suitability for elderly and high-risk patient groups
- Shorter hospital stay and rapid rehabilitation
- Lower risk of complications compared to surgical valve replacement
Technological improvements—such as enhanced sealing skirts, improved leaflet durability, and better delivery systems—have significantly increased success rates and expanded TAVR eligibility to intermediate- and low-risk patient populations.
As the global elderly population continues to surge, the demand for transcatheter heart valve devices is expected to accelerate further.
Regional Insights: North America Dominates the Market in 2023
The structural heart devices market is divided into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America: The Market Leader
North America held the largest market share in 2023, supported by several strategic advantages:
1. Advanced Healthcare Infrastructure
The region’s large network of advanced cardiology centers and cardiac surgeons drives high procedural volumes.
2. High Adoption of Minimally Invasive Therapies
The U.S. leads the world in TAVR and mitral repair procedures, with rapid uptake supported by strong clinical evidence.
3. Favorable Reimbursement Environment
Medicare and private insurers provide robust reimbursement for TAVR, mitral repair, and other structural interventions, significantly boosting market penetration.
4. Strong Presence of Leading Device Manufacturers
North America—particularly the U.S.—is home to many major medical device innovators including:
- Edwards Lifesciences
- Medtronic
- Boston Scientific
- Abbott
Their R&D capabilities, clinical trial leadership, and widespread distribution networks strengthen regional dominance.
Strategic Landscape: Key Companies Innovating the Structural Heart Devices Market
The competitive ecosystem is characterized by continuous product launches, strategic collaborations, clinical trials, and global expansion initiatives. Major players include:
Leading Companies in the Market
- Edwards Lifesciences Corporation (U.S.)
- Boston Scientific Corporation (U.S.)
- Medtronic (Ireland/U.S.)
- Philips (Japan)
- Merit Medical Systems (U.S.)
- Abbott (U.S.)
- Terumo Corporation (Japan)
Other Important Market Participants
- Teleflex (U.S.)
- Integer Holdings (U.S.)
- Lepu Medical Technology (China)
- Venus Medtech (China)
- Artivion (U.S.)
- TTK (India)
- Cook Medical (U.S.)
- SMT (India)
- Meril Lifesciences (India)
- W.L. Gore & Associates (U.S.)
- Cordis (U.S.)
- Foldax (U.S.)
- Micro Interventional Devices (U.S.)
- Cardiac Dimensions (U.S.)
- HighLife Medical (France)
- Mitralign (U.S.)
- Braile Biomedica (Brazil)
- JenaValve (Germany)
- Corcym (Italy)
- Xeltis (Switzerland)
- InnovHeart SRL (U.S.)
These companies are investing heavily in next-generation valve technologies, transcatheter repair systems, closure devices, and innovative delivery systems to improve patient outcomes and expand treatment options.
Conclusion: A High-Growth Market Driven by Innovation and Expanding Patient Needs
The structural heart devices market is entering a high-growth phase, supported by:
- Rising prevalence of structural heart diseases
- Continued innovation in transcatheter interventions
- Favorable reimbursement ecosystems
- Expanding clinical evidence supporting minimally invasive procedures
- Strong demand from both developed and emerging markets
As technologies evolve and treatment eligibility widens, the structural heart device market will remain one of the most dynamic and impactful sectors in cardiovascular healthcare.
